HIV in Canada: A primer for service providers


Pre-exposure prophylaxis (PrEP)

Key Points

  • The consistent and correct use of oral pre-exposure prophylaxis (PrEP) is a highly effective strategy to help prevent HIV transmission for people at high risk for HIV.
  • PrEP involves the use of antiretroviral drugs starting before and continuing after an HIV exposure, throughout periods of high risk.
  • When PrEP is used consistently and correctly, it is rare to get HIV through sex, and the chance of getting HIV from sharing equipment used to inject drugs is greatly reduced.

Oral PrEP involves the use of antiretroviral drugs by an HIV-negative person to reduce their risk of getting HIV. It is taken in pill form, starting before and continuing after an HIV exposure. Oral PrEP contains two antiretroviral drugs that are also used for HIV treatment: tenofovir (also called TDF) and emtricitabine (also called FTC).

When oral PrEP is taken consistently and correctly, the antiretroviral drugs get into the bloodstream and genital and rectal tissues. This helps prevent HIV from infecting and replicating within the body’s immune cells, but drug levels must remain high. If pills are not taken consistently as prescribed, there may not be enough medication in the body to prevent HIV infection.

For oral PrEP to reduce the risk of transmission, it must be used consistently and correctly. This includes:

  • high adherence to PrEP medications as prescribed;
  • initial HIV testing to ensure a person is HIV negative before starting PrEP, and regular testing while taking PrEP to check they remain HIV negative;
  • having kidney function tested, and getting screened for hepatitis A, B and C before starting PrEP; and
  • regular visits with a healthcare provider after the first month on PrEP and approximately every three months thereafter to be tested for HIV and sexually transmitted infections (STIs), monitored for drug side effects and toxicity in the body, and to receive adherence and risk-reduction counselling.

Oral PrEP should only be used by people who are HIV negative. This is because a person can develop resistance to the drugs in PrEP if they start PrEP when they are HIV positive (and unaware of their positive status). The risk of developing drug resistance is lower in people who start PrEP when they are HIV negative and later become HIV positive while on PrEP.

Although oral PrEP is generally safe and well tolerated, it may cause side effects in some people. Some of the possible side effects include nausea, vomiting, diarrhea, headache and dizziness. These side effects are usually mild and temporary. PrEP may also affect kidney, liver and bone health, but evidence suggests the changes are reversible after stopping PrEP. The long-term effects of using oral PrEP are less well known.

Evidence shows that the consistent and correct use of oral PrEP is a highly effective strategy to reduce the risk of HIV transmission when taken daily by:

  • gay, bisexual and other men who have sex with men (gbMSM)
  • heterosexual men and women
  • people who inject drugs

In addition, some studies have found that an intermittent PrEP strategy, taken on-demand before and after sex, is a highly effective strategy to reduce the risk of sexual HIV transmission among gbMSM. This strategy involves taking two pills two to 24 hours before first sexual activity, followed by one pill taken daily until 48 hours after the last sexual activity. No studies have evaluated the effectiveness of intermittent PrEP in other populations and it is not recommended for people who have vaginal sex or people who inject drugs.

Research shows that adherence (taking medications as prescribed) is crucial for oral PrEP to work. In all trials, higher adherence was associated with greater protection. Ongoing studies in real-world settings continue to show that when oral PrEP is used consistently and correctly it is rare for HIV to be transmitted.

While oral PrEP is effective for all genders when used consistently and correctly, daily adherence may be more important for certain people. There is some evidence showing that PrEP takes longer to reach maximum drug levels in vaginal tissues compared to rectal tissues, and that drug levels are lower in vaginal tissues. This suggests that daily dosing of oral PrEP may be more important for people having vaginal sex to maintain sufficient drug levels in the vagina to help prevent HIV infection.

Though it is rare for HIV to be transmitted when PrEP is used consistent and correctly, there are several well-documented cases of PrEP failure in people who were adherent to PrEP. In most of these cases, the person taking PrEP acquired a rare strain of HIV that was resistant to the drugs in PrEP.


CATIE statement on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV

Oral pre-exposure prophylaxis (PrEP) – CATIE fact sheet

PrEP for understudied populations: Exploring questions about efficacy and safety – Prevention in Focus

8 Questions about PrEP for Guys – CATIE

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

La prophylaxie préexposition au virus de l'immunodéficience humaine : Guide pour les professionnels de la santé du Québec – Ministère de la Santé et des Services sociaux du Québec (French only)

Guidance for the use of Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV acquisition in British Columbia – BC Centre for Excellence in HIV/AIDS

Pre-exposure prophylaxis (PrEP) resources


  1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587–2599.
  2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine. 2012;367(5):399–410.
  3. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2012;367(5):411–422.
  4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–2090.
  5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine 2012;367(5):423–434.
  6. Marrazzo J, Ramjee G, Richardson BA et al. Pre-exposure prophylaxis for HIV infection among African women. New England Journal of Medicine 2015;372:509–518.
  7. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016;387(10013):53–60.
  8. Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–F19.
  9. Spinner C, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge or oral systemic HIV PrEP in humans. Infection. 2015 Oct 15:1–8.
  10. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine. 2012;4(151):151ra125.
  11. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infectious Diseases. 2014;14(9):820–829.
  12. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clinical Infectious Diseases. 2015 Nov 15;61(10):1601–1603.
  13. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Science Translational Medicine. 2011;3(112):112re114.
  14. Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy. 2011;66(2):240–250.
  15. Cottrell ML, Srinivas N, Kashuba AD. Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opinion on Drug Metabolism and Toxicology. 2015; 11: 893–905.
  16. Cottrell MI YK, Prince Ha, Sykes C, et al. Predicting effective Truvada PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides. HIV Research for Prevention (R4P), 2014.
  17. Molina J-M, Capitant C, Spire B, et al. On demand Preexposure Prophylaxis in Men at High risk for HIV-1 Infection. New England Journal of Medicine. 2015;373(23):2237–2246.
  18. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The Lancet HIV. 2017 July 23;4(9):e402–e410. Molina J-M, Ghosn J, Béniguel L, et al. Incidence of HIV-infection in the ANRS Prevenir study in Paris region with daily or on-demand PrEP with TDF/FTC.  22nd International AIDS Conference (AIDS 2018). Amsterdam, the Netherlands, 2018. Oral Abstract WEAE0406LB.
  19. Hoornenborg E, Coyer LN, Achterbergh RCA, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. The Lancet HIV. 2019;6(7):e447-e455. Reyniers T, Nostlinger C, Laga M, et al. Choosing between daily and event-driven pre-exposure prophylaxis: Results of a Belgian PrEP demonstration project. Journal of Acquired Immune Deficiency Syndromes. 2018 Oct 1;79(2):186–194.
  20. Knox DC, Tan DH, Harrigan PR, et al. HIV infection with multi-class resistance despite pre-exposure prophylaxis (PrEP). Conference on Retroviruses and Opportunistic Infections (CROI), 2016. Abstract 169aLB.
  21. Grossman H et al. Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP. HIV Research for Prevention (HIVR4P) 2016 conference, Chicago, October 2016, abstract OA03.06LB.
  22. Hoornenborg E, de Bree GJ. Acute infection with a wild-type HIV-1 virus in a PrEP user with high TDF levels. Conference on Retroviruses and Opportunistic Infections (CROI) 2017), Seattle, abstract 953.
  23. Karasz HN. “Possible rare case of transmission of HIV resistant to pre-exposure prophylaxis (PrEP) medication”. Public Health Insider, Public Health Seattle & King County. March 12, 2018. Available from:
  24. Cohen SE, Sachdev D, Lee s, et al. Acquisition of TDF-susceptible HIV despite high level adherence to daily TDF/FTC PrEP as measured by dried blood spot (DBS) and segmental hair analysis: A case report. ID Week 2018. San Francisco, United States, 2018. Poster No. 1298. Available from:
  25. Colby DJ, Kroon E, Sacdalan C, et al. Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis. Clinical Infectious Diseases. 2018;67(6):962–964.